Could antiphospholipid antibodies contribute to coagulopathy in COVID-19? - 19/08/20
Doi : 10.1016/j.jaad.2020.06.003
Aurora Parodi, MD a, b, Giulia Gasparini, MD a, c, ⁎ 
, Emanuele Cozzani, MD, PhD a, b
, Emanuele Cozzani, MD, PhD a, b a Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
b Ospedale Policlinico San Martino IRCCS, Genoa, Italy
c Department of Experimental Medicine, University of Genoa, Genoa, Italy
∗Correspondence to: Giulia Gasparini, MD, Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore 1, 16132 Genoa, ItalySection of DermatologyDepartment of Health Sciences (DISSAL)University of GenoaVia Pastore 1Genoa16132Italy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 3
P. e249 - septembre 2020 Retour au numéro
Article précédent
- Considerations for dermatology residency applicants underrepresented in medicine amid the COVID-19 pandemic
- Virginia A. Jones, Kayla A. Clark, Payal M. Patel, Adriana Cordova, Maria M. Tsoukas
- Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic
- Donovan G. Kearns, Shelley Uppal, Vipawee S. Chat, Jashin J. Wu
Bienvenue sur EM-consulte, la référence des professionnels de santé.